Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38830994

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Nat Med
Publication date
2024 Aug
First author
Leleu X

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Leleu X
      type
      Author
    2. name
      Hulin C
      type
      Author
    3. name
      Lambert J
      type
      Author
    4. name
      Bobin A
      type
      Author
    5. name
      Perrot A
      type
      Author
    6. name
      Karlin L
      type
      Author
    7. name
      Roussel M
      type
      Author
    8. name
      Montes L
      type
      Author
    9. name
      Cherel B
      type
      Author
    10. name
      Chalopin T
      type
      Author
    11. name
      Slama B
      type
      Author
    12. name
      Chretien ML
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Leleu X
      type
      Author
    2. name
      Hulin C
      type
      Author
    3. name
      Lambert J
      type
      Author
    4. name
      Bobin A
      type
      Author
    5. name
      Perrot A
      type
      Author
    6. name
      Karlin L
      type
      Author
    7. name
      Roussel M
      type
      Author
    8. name
      Montes L
      type
      Author
    9. name
      Cherel B
      type
      Author
    10. name
      Chalopin T
      type
      Author
    11. name
      Slama B
      type
      Author
    12. name
      Chretien ML
      type
      Author
    bibliography ids
    1. nci-bib-7d82e6c53ec1488aea8ef5ae
    book metadata
    content sha256
    416128b8c1a682d5c5e601ef112a37852d8d078e320dc756d36e317f6a52418a
    document type
    citation
    dois
    1. 10.1038/s41591-024-03050-2
    electronic publication date
    display
    2024 Jun 3
    precision
    day
    year
    2024
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:38830994
    immutable id
    pubmed:38830994@416128b8c1a682d5c5e601ef112a37852d8d078e320dc756d36e317f6a52418a
    journal
    abbreviation
    Nat Med
    issn electronic
    1546-170X
    issn print
    1078-8956
    issue
    8
    name
    Nature medicine
    nlm unique id
    9502015
    pages
    2235-2241
    volume
    30
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      38830994
      provenance
      batch id
      3e43afde6f26fc8df6da
      provider
      NCBI PubMed ESummary
      record sha256
      d59c3dafdcb0dea313eda142ba336fe0069378a813e041e2282ff9b5e047e456
      response sha256
      fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
      retrieved at
      2026-09-09T23:48:21.145285+00:00
      publication date
      display
      2024 Aug
      precision
      month
      year
      2024
      publication types
      1. Journal Article
      2. Randomized Controlled Trial
      3. Clinical Trial, Phase III
      4. Multicenter Study
      5. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/38830994/
      title
      Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

      Preserved source evidence · Not medical advice